Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
schoolROCK pediatric belumosudil study in chronic graft versus host disease
2024-511508-18-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label trial of belumosudil in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Sanofi. Primary endpoints: AUC and overall response rate by Week 25 or Cycle 7 Day 1. Planned start Jan 2026; status: authorised.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2024-511508-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511508-18-00.